



Article  (Published Version)
http://sro.sussex.ac.uk
Sacristan-Reviriego, Almudena, Mai Le, Hoang, Georgiou, Michalis, Meunier, Isabelle, Bocquet, 
Beatrice, Roux, Anne-Françoise, Prodromou, Chrisostomos, Bainbridge, James, Michaelides, 
Michel and Spuy, Jacqueline van der (2020) Clinical and functional analyses of AIPL1 variants 
reveal mechanisms of pathogenicity linked to different forms of retinal degeneration. Scientific 
Reports, 10 (1). a17520 1-15. ISSN 2045-2322 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/95907/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17520  | https://doi.org/10.1038/s41598-020-74516-9
www.nature.com/scientificreports
Clinical and functional analyses 
of AIPL1 variants reveal 
mechanisms of pathogenicity 
linked to different forms of retinal 
degeneration
Almudena Sacristan‑Reviriego1, Hoang Mai Le1, Michalis Georgiou1,2, Isabelle Meunier3, 
Beatrice Bocquet3, Anne‑Françoise Roux4, Chrisostomos Prodromou5, James Bainbridge1,2, 
Michel Michaelides1,2 & Jacqueline van der Spuy1*
Disease‑causing sequence variants in the highly polymorphic AIPL1 gene are associated with a broad 
spectrum of inherited retinal diseases ranging from severe autosomal recessive Leber congenital 
amaurosis to later onset retinitis pigmentosa. AIPL1 is a photoreceptor‑specific co‑chaperone that 
interacts with HSP90 to facilitate the stable assembly of retinal cGMP phosphodiesterase, PDE6. In 
this report, we establish unequivocal correlations between patient clinical phenotypes and in vitro 
functional assays of uncharacterized AIPL1 variants. We confirm that missense and nonsense 
variants in the FKBP‑like and tetratricopeptide repeat domains of AIPL1 lead to the loss of both 
HSP90 interaction and PDE6 activity, confirming these variants cause LCA. In contrast, we report 
the association of p.G122R with milder forms of retinal degeneration, and show that while p.G122R 
had no effect on HSP90 binding, the modulation of PDE6 cGMP levels was impaired. The clinical 
history of these patients together with our functional assays suggest that the p.G122R variant is a 
rare hypomorphic allele with a later disease onset, amenable to therapeutic intervention. Finally, 
we report the primate‑specific proline‑rich domain to be dispensable for both HSP90 interaction and 
PDE6 activity. We conclude that variants investigated in this domain do not cause disease, with the 
exception of p.A352_P355del associated with autosomal dominant cone‑rod dystrophy.
The aryl hydrocarbon receptor interacting protein-like 1 (AIPL1) is a retinal photoreceptor-specific protein 
expressed in cones and  rods1,2. AIPL1 acts, in concert with HSP90, as a specialized molecular co-chaperone for 
cGMP-specific phosphodiesterase-6 (PDE6), a key effector of the visual phototransduction  cascade3–6. AIPL1 
facilitates the stability and catalytic activity of heterologously expressed cone and rod  PDE63,5. Studies in mice 
have shown that in the absence of AIPL1, the levels of cone and rod PDE6 are markedly  reduced7–9 and the PDE6 
subunits are misassembled and targeted to proteasomes for  degradation10. The increased levels of cGMP trigger 
rapid degeneration of photoreceptors and, as a result, electroretinography (ERG) responses are extinguished at 
any age tested in the absence of  AIPL19,11. Interestingly, disease-causing sequence variants in PDE6 also cause 
increased levels of cGMP and subsequent retinal  degeneration12–16.
The 384-amino acid protein AIPL1 is composed of an N-terminal FK506-binding protein (FKBP)-like 
domain, a tetratricopeptide repeat (TPR) domain and a primate-specific C-terminal proline rich domain (PRD). 
The TPR domain, comprising three TPR motifs, is responsible for the interaction of AIPL1 with HSP90, which 
is facilitated by the TPR-acceptor site EEVD located at the C-terminus of  HSP904,5. The N-terminal FKBP-like 
domain of AIPL1 facilitates the interaction with the C-terminal isoprenyl (farnesyl and geranylgeranyl) moieties 
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present in PDE6 subunits due to posttranslational  modifications17–20. Thus, variants compromising the integrity 
and relative orientation of the AIPL1 FKBP-like or TPR domain fail to efficiently modulate PDE6 activity in vitro 
through  HSP905.
Biallelic variants in the AIPL1 gene are predominantly associated with autosomal recessive Leber congenital 
amaurosis (LCA), a congenital-onset, rapid and progressive retinal degeneration leading to the severe impair-
ment or loss of vision within the first few years of  life21–24. Interestingly, there are reports of less severe later onset 
retinal degeneration diagnoses such as retinitis pigmentosa (RP) linked to biallelic AIPL1  variants25. Moreover, 
a heterozygous 12-bp deletion leading to a protein lacking four amino acids in the PRD has been reported to be 
a cause of autosomal dominant cone-rod dystrophy (adCORD) and early-onset  RP26.
LCA-associated AIPL1 sequence variants to date include missense and nonsense variants, as well as small 
insertions and duplications, small deletions and splice alterations. Interestingly, missense variants in the very 
first or last nucleotides of exons, as well as small insertions or duplications spanning intron–exon boundaries, 
have been shown to induce aberrant pre-mRNA AIPL1 splicing, thereby resolving the disease-causing status and 
pathogenic mechanisms for these sequence  variants27. Presently, the Human Gene Mutation Database (HGMD)28, 
the ClinVar  database29 and the Ensembl  project30 have recorded 83, 125 and 32 AIPL1 variants respectively. 
Several of these are considered likely to be benign or rare ethnic benign single nucleotide polymorphisms, while 
several other variants are still of uncertain or conflicting pathogenicity. Confirmation of true disease-associated 
AIPL1 variants is therefore a challenge confounded by the polymorphic nature of the gene and remains crucial 
for patient diagnosis and potential AIPL1-targeted gene replacement  therapies31.
In this study, we determined the disease-causing status of novel and previously reported but uncharacterized 
AIPL1 variants, and established a correlation between clinical phenotypes and the underlying pathogenic mecha-
nisms through in vitro functional assays. We confirm the disease-causing status of several variants investigated 
and the possibility of rare hypomorphic alleles, thus clarifying the prospects for therapeutic intervention for 
patients harbouring these variants.
Results
Molecular genetics. In this study, a total of 21 AIPL1 sequence variants were investigated, including mis-
sense (n = 14) and nonsense (n = 3) variants, as well as small insertions (n = 1), duplications (n = 2) and deletions 
(n = 1) in the coding sequence (Tables 1 and 2; full clinical details in Suppl. Table 1). These variants have been 
identified in patients in previously reported studies or this study. Ten of the sequence variants investigated have 
been identified in a homozygous or compound heterozygous state in patients with molecularly confirmed bial-
lelic variants in AIPL1 (Table 1, Suppl. Table 1). Thirteen sequence variants, 2 of which were also reported in 
Table 1.  Clinical information of patients with AIPL1 variations: Patients with AIPL1 variations identified 
on both alleles. The AIPL1 variants investigated in this study are shown in BOLD. LCA, Leber congenital 
amaurosis; EOSRD, early-onset severe retinal dystrophy; RP, retinitis pigmentosa; *, novel variation.
Case Allele 1 Allele 2 Clinical diagnosis References
P1 c.116C>A; p.T39N c.116C>A; p.T39N LCA 32
P2 c.214T>C; p.W72R c.265T>C; p.C89R LCA 25
P3 c.266G>A; p.C89Y c.266G>A; p.C89Y LCA 33
P4 c.364G>A; p.G122R c.834G>A; p.W278X LCA 34
P5 c.364G>A; p.G122R c.364G>A; p.G122R RP This study
P6 c.364G>C; p.G122R c.834G>A; p.W278X RP/late onset retinal degeneration 25
P7 c.364G>C; p.G122R c.834G>A; p.W278X Mild RP This study
P8 c.364G>C; p.G122R c.834G>A; p.W278X Mild RP This study
P9 c.582C>G; p.Y194X c.834G>A; p.W278X LCA 35
P10* c.666G>A; p.W222X* c.834G>A; p.W278X LCA This study
P11 c.733G>T; p.E245X c.834G>A; p.W278X LCA 35
P12 c.809G>A; p.R270H c.834G>A; p.W278X LCA 36
P13 c.809G>A; p.R270H c.834G>A; p.W278X LCA 34
P14 c.809G>A; p.R270H c.834G>A; p.W278X LCA 33
P15 c.926_927ins CCT GAA CCG CAG GGA GCT; p.E309DinsLNRREL
c.926_927ins CCT GAA CCG CAG GGA GCT; 
p.E309DInsLNRREL LCA
37
P16 c.1126C>T; p.P376S c.341C>T; p.T114I LCA 26
P17 c.1126C>T; p.P376S c.341C>T; p.T114I LCA 23
P18 c.1126C>T; p.P376S c.341C>T; p.T114I LCA 23
P19 c.1126C>T; p.P376S c.341C>T; p.T114I EOSRDLCA
38
P20 c.1126C>T; p.P376S c.341C>T; p.T114I EOSRD
39
This study
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patients with biallelic variants, have been identified on only a single allele in patients with no change identified 
on the other allele (Table 2, Suppl. Table 1).
Clinical phenotype of AIPL1‑associated cases. Patients with biallelic AIPL1 sequence variants. The 
majority of patients with biallelic AIPL1 variants were diagnosed with LCA (Table  1, Suppl. Table  1). These 
patients have severely reduced visual acuity, ranging from 20/400 to perception of light (PL), variable pigmen-
tary changes and macular atrophy on fundoscopy, and undetectable or markedly diminished rod and cone 
ERGs (Suppl. Table 1). P10 was compound heterozygous for c.834G>A (p.W278X) and a novel AIPL1 variant 
c.666G>A (p.W222X) identified in this study. This patient was diagnosed with LCA, with congenital onset and 
complete loss of the neurosensory retina by the age of five years (Fig. 1).
P19, P20 and P21 were diagnosed with early onset severe retinal dystrophy (EOSRD), with P20 having milder 
disease compared to P21 (no clinical details available for P19). The c.1126C>T (p.P376S) sequence variant was 
detected in each of these patients either homozygously (P21) or heterozygously together with c.341C>T (p.T114I) 
(P19, P21). The VA in these patients ranged from 6/19 to PL (Suppl. Table 1).
P5-P8 did not have a phenotype within the LCA/EOSRD spectrum. P5 was homozygous for a c.364G>A 
(p.G122R) sequence variant and has RP (this study) (Fig. 2, Suppl. Fig. 1). The patient presented with nyctalopia 
since early childhood with a VA at 34 years old of 20/50 in the right eye and 20/100 in the left eye. Interest-
ingly, P4 is compound heterozygous for the same c.364G>A (p.G122R) variant on one allele and the common 
disease-causing variant c.834G>A (p.W278X) on the other allele, but was diagnosed with  LCA34. P6-P8 were 
all diagnosed with late onset retinal degeneration or RP and all harbour a different missense variant coding for 
the same amino acid change (c.364G>C (p.G122R)) as P4 and P5 on one allele, together with the c.834G>A 
(p.W278X) sequence variant on the other allele. P6 is a previously reported case with severely decreased VA 
(20/60, 20/400), undetectable ERG and a diagnosis of late onset retinal degeneration or  RP25. P7 (Fig. 3, Suppl. 
Fig. 1) and P8 (Suppl. Fig. 2) are siblings and presented with nyctalopia and mild signs of RP with unaffected 
visual acuity (20/20) (this study). 
Patients with monoallelic AIPL1 sequence variants. Thirteen heterozygous AIPL1 sequence variants previously 
reported in patients with retinal degeneration but without detailed phenotyping and with no AIPL1 changes 
identified in the coding regions or intron/exon boundaries of the other allele were also investigated (Table 2, 
Suppl. Table 1). Two of these sequence variants, c.214T>C (p.W72R) and c.1126C>T (p.P376S), were also found 
in patients with biallelic AIPL1 variants (see Table 1: Patients with AIPL1 variations identified on both alleles). 
All available clinical features are summarised in Suppl. Table 1.
Table 2.  Clinical information of patients with AIPL1 variations: Patients with a single AIPL1 variation 
identified on one allele. The AIPL1 variants investigated in this study are shown in BOLD. LCA, Leber 
congenital amaurosis; EOSRD, early-onset severe retinal dystrophy; RP, retinitis pigmentosa; adCORD; 
autosomal dominant cone-rod dystrophy; N/A, not available;* , did not segregate with disease.
Case Allele 1 Allele 2 Clinical diagnosis References
P22 c.157C>T; p.R53W N/A LCA 40
P23 c.214T>C; p.W72R N/A LCA 41
P24 c.390C>A; p.H130Q N/A EOSRDLCA
39
P25 c.593C>T; p.S198F N/A EOSRDLCA
39
P26 c.617T>A; p.I206N N/A LCA 40
P27 c.878T>C, p.L293P N/A LCA 41
P28 c.894G>C; p.Q298H N/A EOSRDLCA
39




P30 c.1091C>G; p.A364G N/A EOSRDLCA
39
P31 c.1097C>G; p.P366R N/A EOSRDLCA
39
P32 c.1103_1114dup; p.E369_T372dup N/A LCA 41
P33 c.1111_1122dup; p.A371_P374dup N/A LCA 42




Cis-allelic inheritance from mother
N/A LCA 43
P36 c.1126C>T; p.P376S N/A EOSRD
39
This study
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The majority of patients were diagnosed with LCA/EOSRD. The sequence variant c.1053_1064del12pb 
(p.A352_P355del) was previously reported to cause adCORD or early-onset  RP26 (Table 2, Suppl. Table 1). P36 
and P37, harbouring a heterozygous c.1126C>T (p.P376S) change, were diagnosed with EOSRD or EOSRD/RP 
respectively. Interestingly, a c.1126C>T (p.P376S) heterozygous change was previously reported not to segregate 
with  disease41 and Coppieters et al.43 reported the maternal cis-allelic inheritance of c.1126C>T (p.P376S) and 
c.341C>T (p.T114I) (Table 2, Suppl. Table 1).
In silico analysis and allele frequencies of AIPL1 variants. The in silico analysis of the AIPL1 vari-
ants resulting from missense changes are summarized in Table 3. Most of the variants investigated in this study 
fall in the category of damaging according to both the SIFT tolerance index and Polyphen HumVar Score with 
the exception of the p.A364G variant, which is scored as tolerated/benign. There is a discrepancy in the results 
obtained for p.Q298H and p.P376S variants, which are scored as tolerated by one program and damaging by 
Figure 1.  Longitudinal optical coherence tomography (OCT) imaging in an LCA patient with AIPL1 c.666G>A 
(p.W222X)/c.834G>A (p.W278X) variants. (a) Transfoveal OCT image of the right eye at baseline. The yellow 
arrowheads mark the temporal and nasal borders of the external limiting membrane (ELM). There is extensive 
loss of photoreceptors and loss of the ellipsoid zone (EZ). The green arrowhead marks the residual EZ over the 
foveal center. The red borders mark the region of interest shown at higher magnification (× 2) in (b), where 
the ELM is marked with yellow arrowheads and the remnants of photoreceptors with a green arrowhead. After 
2 years follow-up (c), no ELM or EZ remnants were identified and the retinal thickness was decreased compared 
to (b). Visual acuity was hand motion at 30 cm at baseline and perception of light at follow-up. yo; years old.
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the other. Analysis of the allele frequency of AIPL1 missense and nonsense sequence variations show that all 
the AIPL1 variants investigated are very rare (allele frequency < 1/10,000) and have not been observed in the 
homozygous state in the current Exome Aggregation Consortium (ExAC) and the Genome Aggregation Data-
base (gnomAD) with the exception of c.1126C>T (p.P376S), detected in 27 and 51 homozygotes respectively, 
and a frequency of 59–62 per 10,000.
Expression and subcellular distribution of AIPL1 variants. We first examined the expression and 
subcellular localization of the AIPL1 variants described above by immunofluorescent confocal microscopy 
(Fig.  4) and western blotting (Fig.  5). The myc-tagged AIPL1 variants p.T39N, p.W72R, p.C89Y, p.G122R, 
p.H130Q, p.Y194X, p.S198F, p.I206N, p.W222X, p.E245X, p.R270H, p.L293P, p.Q298H, p.A364G, p.E309Dins, 
p.A352_P355del, p.E369_T372dup, p.P366R, p.A371_P374dup and p.P376S showed a homogeneous subcellu-
lar cytoplasmic distribution similar to wildtype (w/t) AIPL1 (Fig. 4). The p.R53W variant formed intracellular 
inclusions (Fig. 4) and was not detected by immunoblotting (Fig. 5), pointing to the misfolding of the p.R53W 
variant to detergent insoluble aggregates that could not be resolved by denaturing SDS-PAGE. This mutation 
drastically alters the charge at a highly conserved residue within a single turn α helix (αt) between the β3 and β4 
strands of the FKBP-like  domain19, thus most likely having a detrimental impact on the folding of this domain.
The analysis of expression by western blotting with an anti-myc antibody directed against the N-terminal 
myc tag revealed that the levels of expression of most of the AIPL1 variants investigated were similar to w/t 
AIPL1 in the soluble fraction except for the nonsense variants p.Y194X, p.W222X and p.E245X, whose levels 
were decreased (Fig. 5a). These variants, resulting in a large C-terminal truncation, were not detected by western 
blotting with the anti-hAIPL1 antibody directed against the C-terminal AIPL1-specific epitope (Fig. 5b). Reduced 
levels of the variant p.P376S were detected with the C-terminal anti-hAIPL1 antibody, most likely due to dis-
ruption of the anti-hAIPL1  epitope1. Full blots and relative quantitation of the levels are shown in Suppl. Fig. 3.
Analysis of AIPL1 function. AIPL1 acts as a specific retinal co-chaperone that interacts with the molecu-
lar chaperone  HSP904,5. Therefore, we investigated the ability of the AIPL1 variants to bind recombinant HSP90α 
and HSP90β by performing quantitative ELISA experiments (Fig. 6a). The mean of the absorbance at 450 nm 
of each AIPL1 variant was normalized to the level of expression in the cell lysate and the results in Fig. 6a are 
calculated relative to w/t AIPL1. AIPL1 variants in the FKBP-like domain are shown as dark grey bars, in the 
TPR domain as white bars, in the region between the TPR and PRD as striped bars and in the PRD as light grey 
bars. The AIPL1 variants p.T39N, p.W72R, p.C89Y, p.Y194X, p.S198F, p.I206N, p.W222X, p.E245X, p.R270H, 
p.L293P, p.E309Dins, p.A364G and p.P376S had a statistically significant reduction of the interaction with both 
isoforms of HSP90 (α and β) compared with w/t AIPL1, while p.G122R, p.H130Q, p.Q298H, p.A352_P355del, 
p.P366R, p.E369_T372dup and p.A371_P374dup are not compromised in binding. AIPL1 variants affecting the 
Figure 2.  A 34-year-old man with a retinitis pigmentosa phenotype carrying a homozygous AIPL1 c.364G>A 
(p.G122R) variant. Nyctalopia since early childhood was described by the patient. Visual acuity was 20/50 in the 
right eye and 20/100 in the left eye. (a,b) Infrared reflectance imaging. The retinal vessel diameters are reduced 
with bone-spicule-like pigmentation in the peripheral retina (white arrows). Fundus autofluorescence revealed 
multiple hypoautofluorescent spots within the peripheral retina. There was no macular ring of increased signal, 
but small hypoautofluorescent lesions were seen within the fovea (white arrows).
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TPR domain, including the missense mutants p.S198F and p.R270H and the premature translation termination 
mutants p.Y194X, p.W222X and p.E245X, had the greatest impact on HSP90 interaction as expected. Next, we 
investigated the impact of the AIPL1 variants on PDE6 activity using heterologous expression of functional 
rod PDE6 in HEK293T cells (Fig. 6b). We conducted our assays in the presence of the two catalytic subunits 
(PDE6α and PDE6β) and the regulatory subunit PDE6γ as described previously in Sacristan-Reviriego et al.5. 
Using a cGMP ELISA assay, we show that the PDE6 holoenzyme alone increased intracellular cGMP levels 
above background, and that the co-expression of AIPL1 with the PDE6 holoenzyme significantly increased the 
cGMP levels above the basal PDE6 levels. Analysis of the AIPL1 variants revealed that the p.T39N, p.W72R and 
p.C89Y variants in the FKBP-like domain had the greatest impact on cGMP levels and were completely unable to 
modulate these levels above PDE6 basal levels, whilst the impact of the FKBP-like domain variants p.G122R and 
p.H130Q was less significant. Interestingly, all the variants in the TPR domain and the p.E309Dins between the 
Figure 3.  An 18-year-old woman with a retinitis pigmentosa phenotype with AIPL1 c.364G>C (p.G122R)/
c.834G>A (p.W278X) variants. Nyctalopia was the first symptom, noted at the age of 5 years. Visual acuity 
was 20/20 in both eyes and the patient did not report peripheral or central visual field loss. (a) Colour fundus 
photography in the right eye and (b) reflectance infrared imaging of the left eye: note mild reduced diameter 
of the retinal vessels and the lack of bone-spicule-like pigmentation in the peripheral retina. (c,d) Fundus 
autofluorescence imaging disclosed a macular hyperautofluorescent ring (white arrows) and few peripheral 
hypoautofluorescent spots (red arrows). (e,f) On SD-OCT, there was extensive loss of the photoreceptor/retinal 
pigment epithelium complex and the ellipsoid zone (EZ). EZ and the interdigitation zone are only visible at the 
fovea (between blue arrows) in accordance with the visual acuity of 20/20.
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TPR domain and PRD also had an impact on cGMP levels, with the p.R270H variant unable to modulate cGMP 
level above basal levels. The variant p.Q298H between the TPR domain and PRD was as efficient as w/t AIPL1 
in modulating cGMP levels. Within the PRD, none of the variants investigated led to a deficit in the modulation 
of cGMP levels compared to w/t AIPL1.
The FKBP and the TPR domains of AIPL1 are essential for its functional activity. The role of the 
PRD and its contribution to AIPL1-associated pathogenesis are poorly understood. Therefore, we examined how 
the lack of the PRD domain, the FKBP-like domain or both the FKBP-like and PRD affect the ability of AIPL1 
to bind HSP90 and promote the proper assembly and activity of PDE6. For that purpose, we engineered three 
different constructs: p.S328X (ΔPRD) including the FKBP-like and TPR domains (FKBP + TPR), p.M1_N168del 
(ΔFKBP) including the TPR domain and PRD (TPR + PRD) and p.N168-S328X (ΔFKBP + ΔPRD) including 
only the TPR domain (TPR). Immunofluorescent confocal microscopy (Fig. 7a) and western blotting (Fig. 7b) 
of transfected cells showed a normal cellular distribution and expression of all three constructs, as compared to 
w/t AIPL1. Quantitative ELISA experiments revealed that the lack of the PRD or FKBP domain did not reduce 
the binding of AIPL1 with recombinant HSP90α and HSP90β (Fig. 7c). Interestingly, the TPR domain alone 
interacted significantly better with HSP90α/β, showing a two-fold increase over w/t AIPL1. We further inves-
tigated the impact of the AIPL1 domains on cGMP levels following the heterologous expression of rod PDE6 
(Fig. 7d). The lack of the PRD domain did not have any effect on PDE6 activity therefore this domain appears to 
be completely dispensable for this function (Fig. 7d) as well as for the interaction with HSP90 (Fig. 7c). On the 
contrary, the expression of TPR + PRD or TPR alone could not restore cGMP levels to that seen with full length 
w/t AIPL1, confirming that the FKBP domain is absolutely essential.
Discussion
This study reports the functional assessment of bi- or monoallelic AIPL1 sequence variants, associated with a 
broad range of retinal diseases, including autosomal recessive LCA and RP, and autosomal dominant CORD and 
RP. AIPL1 sequence variants investigated include missense and nonsense variations, as well as small insertions, 
duplications and deletions in the coding sequence (Fig. 8).
With the exception of p.G122R and p.H130Q, our data show that all variants in the FKBP-like domain 
(p.T39N, p.W72R, p.C89Y) (Fig. 8) and in the TPR domain (p.Y194X, p.S198F, p.I206A, p.W222X, p.E245X, 
p.R270H, p.L293P) (Fig. 8) are defective both in their ability to mediate an interaction with HSP90 and to 
modulate cGMP levels. We therefore confirm that these variants are disease-causing in accordance with all 
available evidence, including their allele frequency, in silico predictions of pathogenicity, and association with 
Table 3.  Allele frequencies and in silico predictions of the AIPL1 variants investigated. The cDNA is 
numbered according to the longest AIPL1 transcript ENST00000381129, protein ID ENSP00000370521. 
ExAC allele count: Allele frequency of the AIPL1 variations in a reference data set derived from 61,486 
unrelated individuals sequenced as part of various disease-specific and population genetic studies; excludes 
cases of severe pediatric disease. The dataset provided in gnomAD includes 125,748 exome sequences 
and 15,708 whole-genome sequences from unrelated individuals sequenced as part of various disease-
specific and population genetic studies. SIFT results: tolerance index ≥ 0.05 = tolerated (T), tolerance 
index < 0.05 = damaging (D). PolyPhen-2: benign, possibly damaging (p.D), probably damaging (P.D). N/A, not 
applicable; nd, not described.




ExAC gnomAD ExAC gnomAD
c.116C>A p.T39N D 0.05 P.D 1 nd nd nd nd
c.157C>T p.R53W D 0 P.D 0.96 0.000008358 0.00004246 0 0
c.214T>C p.W72R D 0 P.D 1 nd nd nd nd
c.266G>A p.C89Y D 0 P.D 1 nd 0.000003996 nd 0
c.364G>A p.G122R D 0 P.D 1 0.00000834 0.000003988 0 0
c.390C>A p.H130Q D 0 P.D 0.998 nd 0.000003992 nd 0
c.582C>G p.Y194X N/A N/A 0.000008238 0.000003976 0 0
c.593C>T p.S198F D 0.01 p.D 0.627 nd nd nd nd
c.617T>A p.I206N D 0.03 P.D 0.953 nd nd nd nd
c.666G>A p.W222X N/A N/A nd nd nd nd
c.733G>T p.E245X N/A N/A nd nd nd nd
c.809G>A p.R270H D 0 P.D 1 nd nd nd nd
c.878T>C p.L293P D 0 P.D 1 nd nd nd nd
c.894G>C p.Q298H T 0.11 p.D 0.721 nd nd nd nd
c.1091C>G p.A364G T 0.1 Benign 0.001 nd nd nd nd
c.1097C>G p.P366R D 0.02 p.D 0.637 nd nd nd nd
c.1126C>T p.P376S D 0 Benign 0.001 0.00588 0.006198 27 51
8
Vol:.(1234567890)
Scientific Reports |        (2020) 10:17520  | https://doi.org/10.1038/s41598-020-74516-9
www.nature.com/scientificreports/
Figure 4.  Subcellular localization of AIPL1 variants. Indirect immunofluorescent confocal microscopy using 
anti-myc antibody against the N-terminus of AIPL1. The misfolding and aggregation of p.R53W to visible 
intracellular inclusions is shown at higher magnification as an insert. Scale bar: 10 μm.
Figure 5.  Expression of AIPL1 variants. Western blotting analysis of wild-type (w/t) AIPL1 and the indicated 
AIPL1 variants. The proteins were resolved by SDS-PAGE on a 12% gel. (a) The anti-myc antibody recognizes 
the myc tag fused to the N-terminus of AIPL1. (b) The anti-AIPL1 antibody is directed against a C-terminal 
AIPL1  epitope1. GAPDH was detected as a loading control. *Demarcates an in silico designed AIPL1 variant not 
found in patients and not associated with disease.
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Figure 6.  Functional analysis of AIPL1 variants. (a) Interaction of AIPL1 variants with HSP90. Quantitative 
ELISA analysis of the interaction between wild-type (w/t) AIPL1 or the AIPL1 variants indicated with purified 
human recombinant HSP90α and HSP90β. The absorbance of each interaction was normalized to the expression 
level detected by western-blotting and plotted relative to w/t AIPL1 = 1.0. (b) Heterologous rod PDE6 activity 
in the presence of the AIPL1 variants. Quantitative analysis of the cGMP concentration from cells expressing 
the PDE6 holoenzyme (α, β and γ) alone, and in the presence of w/t AIPL1 or AIPL1 variants as indicated. 
Independent assays were performed three or more times with samples analysed in triplicate in each assay. 
All AIPL1 variants showed statistically significant differences (p ≤ 0.01) with respect to w/t AIPL1 with the 
exception of the variants demarcated by NS (p > 0.01).
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severe disease (LCA) in patients. We also report a novel disease-causing variant in AIPL1, c.666G>A (p.W222X), 
causing severe retinal degeneration (Fig. 1) and early loss of vision. Notably, the p.Y194X, p.S198F, p.W222X, 
p.E245X, and p.R270H variants in the TPR domain had the greatest impact on the interaction with HSP90, whilst 
p.T39N, p.W72R and p.C89Y in the FKBP-like domain had the greatest impact on the modulation of cGMP 
levels. However, sequence variants in the TPR domain also had an impact on the modulation of cGMP levels, 
and reciprocally, variants in the FKBP-like domain had an impact on HSP90 interaction. Our functional assays 
thus show that the FKBP-like and TPR domains are important for both HSP90 interaction and the modulation 
of cGMP levels. This confirms our previously reported conclusions that the relative conformational organization 
and orientation of these domains is important and necessary for AIPL1  function5.
Within the linker between the TPR domain and PRD, the c.894G>C (p.Q298H) sequence variant has been 
reported as a rare heterozygous change in a single patient with no second allele identified by direct sequenc-
ing of the AIPL1  gene39. The in silico predictions of p.Q298H pathogenicity are inconclusive, and in this study, 
p.Q298H was consistently comparable to wild type AIPL1 in all assays, with no deficit in HSP90 binding or cGMP 
modulation. We therefore conclude that c.894G>C (p.Q298H) is a rare benign polymorphism. This is supported 
by the fact that p.Q298H occurs in the loop connecting the 6th and 7th α-helix of the TPR domain and it is 
solvent exposed (Fig. 8). In contrast, p.E309DinsLNRREL had a significant impact on both HSP90 interaction 
Figure 7.  Functional characterization of AIPL1 domains. Subcellular localization and expression of AIPL1 
domains. (a) Indirect immunofluorescent confocal microscopy and (b) western blotting analysis using anti-
myc antibody. (c) Quantitative ELISA analysis of the interaction of AIPL1 domains with purified human 
recombinant HSP90α and HSP90β. The absorbance of each interaction was normalized to the expression level 
detected by western-blotting and plotted relative to w/t AIPL1 = 1.0. (d) Quantitative analysis of the cGMP 
concentration from cells expressing the PDE6 holoenzyme (α, β and γ) in the presence of AIPL1 domains. 
Assays were performed in triplicates. Statistically significant differences with respect to w/t AIPL1 are indicated 
by asterisks (*p < 0.05, **p < 0.01 and ***p < 0.001).
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and cGMP modulation. The c.926_927insCCT GAA CCG CAG GGA GCT (p.E309DinsLNRREL) sequence vari-
ant was reported as a homozygous change in an LCA patient with undetectable ERG responses and significantly 
attenuated visual acuity (hand motion)37, altogether confirming the disease-causing status and association of 
this variation with LCA. The insertion maps to the distal end of the 7th α helix of the TPR  domain44 (Fig. 8), and 
is expected to considerably disrupt the topology of this domain.
The variants p.G122R and p.H130Q in the FKBP-like domain are unique amongst the variants investigated 
in this study, in that while they had no impact on HSP90 interaction, they were significantly compromised with 
respect to the modulation of cGMP levels. The p.G122R variant has been reported in association with the milder 
phenotypes of late onset retinal degeneration or RP. In this study, we report a pair of siblings that are compound 
heterozygous for c.364G>C (p.G122R) and c.834G>A (p.W278X) diagnosed with mild RP. Similarly, Jacobson 
et al.25 reported a patient with the same biallelic AIPL1 variants who was first evaluated at the age of 45 years, 
presenting with widespread later onset retinal degeneration and macular involvement. In addition, we report 
a patient that presented with RP at the age of 34 years, who was homozygous for a different nucleotide change 
(c.364G>A) coding for the same p.G122R variant. This c.364G>A (p.G122R) sequence variant has also been 
reported in a patient compound heterozygous for c.834G>A (p.W278X)34; who presented at the age of 79 years 
with an extinguished ERG and visual acuity of hand motion in both eyes. Collectively, the clinical data combined 
with our functional assays suggest that the p.G122R variant is associated with a milder later-onset but progres-
sive form of retinal degeneration, and may thereby behave as a rare hypomorphic allele. Hypomorphic variants 
in other genes including RPE65, CEP290, NMNAT1 and ABCA4 have also recently been associated with milder 
forms of inherited retinal disease with slower progression (later onset)45–49. Similar to p.G122R, the variant 
p.H130Q had no effect on HSP90 binding but was significantly compromised with respect to cGMP modulation. 
Whilst detailed clinical data is absent for the patient harbouring this variant, our data suggest that p.H130Q, like 
p.G122R, may behave as a rare hypomorphic variant. Both p.G122R and p.H130Q are located within an insert 
region between residues 90 and leucine 146 unique to the FKBP-like domain of AIP and AIPL1 that may act 
as a flexible lid to occlude the ligand-binding hydrophobic  cavity17,19,20,50 (Fig. 8). The insert region of AIPL1 is 
well structured and comprised of three α helices (α2, α3, α4)19. G122 and H130 are located in the middle and 
immediately distal to the α3 helix in the insert region (Fig. 8). Deletion of residues 111 to 132 (encompassing 
G122 and H130) in the insert region had no structural impact on the FKBP-like domain, but completely abol-
ished the interaction with an isoprenyl group due to the loss of extensive α2 residue side-chain contributions 
to ligand  binding17,19. Interestingly, molecular dynamics simulations revealed α3 to be the most flexible region 
of the FKBP-like domain, favouring occlusion to the entrance of the hydrophobic ligand-binding cavity in a 
dynamic and intermittent  fashion19. We propose therefore, that p.G122R and p.H130Q do not contribute to, or 
significantly impact, the binding of the isoprenyl group, but may alter the conformation of the lid and acces-
sibility to the hydrophobic ligand binding cavity, thus modulating, but not severely impacting AIPL1 function.
The variants within the primate-specific PRD of AIPL1 require special consideration, as the role of the PRD 
remains unresolved. The PRD of human AIPL1 is an extended and unstructured random coil that lacks secondary 
 structure18 (Fig. 8). Previously, Li et al.51 reported that while the PRD did not impact the structural properties and 
thermal stability of AIPL1, deletion of the PRD enhanced the affinity of AIPL1 for full length HSP90, suggesting 
that the PRD may have an inhibitory effect on HSP90 binding. Our data also show that the greatest HSP90 bind-
ing efficiency is achieved with the TPR domain alone. However, compared to full length wild-type AIPL1, we 
show that the PRD is completely dispensable for both the interaction with HSP90 and the modulation of PDE6 
activity. Similarly, deletion of the PRD domain has been shown to have no effect on the interaction of AIPL1 with 
the HSP90 C-terminal peptide TSRMEVEED or the interaction of AIPL1 with a farnesylated and carboxymeth-
ylated C-terminal PDE6α  peptide18. In accordance with these data, we show that all the variants investigated in 
Figure 8.  PyMol cartoon of an AIPL1 phyre2 model showing the location of mutations. The domains of AIPL1 
are coloured as FKBP-like domain (yellow), TPR1 (gold), TPR2 (blue), TPR3 (cyan), helix 7 of the TPR domain 
(green) and PRD (salmon). Linkers between domains are shown in grey. Mutations that involve a C-terminal 
truncation or deletion are also indicated in red text, insertions in cyan text and duplications in green text.
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the PRD domain (p.A352_P355del; p.A364G; p.P366R; p.E369_T372dup; p.A371_P374dup; p.P376S) had either 
a minimal or no significant effect on binding HSP90, and did not compromise the modulation of cGMP levels, 
pointing to these variants either having no role in disease or contributing to pathogenesis via a different and as 
of yet uncharacterised mechanism.
In patients, the PRD variants, with the exception of c.1126C>T (p.P376S), have been identified as monoal-
lelic variants in association with a range of different clinical phenotypes, including LCA, EOSRD, adCORD, 
early-onset RP and RP. Indeed, c.1126C>T (p.P376S) has been reported in patients as a homozygous, compound 
heterozygous or heterozygous change associated with LCA, EOSRD, or RP. Interestingly, in all reported patients 
that are compound heterozygous for c.1126C>T (p.P376S), the other sequence variant is invariably c.341C>T 
(p.T114I) in these patients, and the maternal cis-allelic inheritance of c.1126C>T (p.P376S) and c.341C>T 
(p.T114I) has been reported in one patient. This suggests that c.1126C>T (p.P376S) and c.341C>T (p.T114I) are a 
common haplotype, the inheritance of which exceeds the frequency with which one would expect these variants 
to occur together in a rare autosomal recessive disease. Indeed, the allele frequency of c.1126C>T (p.P376S) is 
higher than expected with 27 and 51 homozygotes detected in ExAC and gnomAD respectively. This variant has 
also been shown not to segregate with  disease41. Our results show that p.P376S has no impact on cGMP levels 
in our functional assays, and we conclude that this variation is not associated with disease in these patients. 
Similarly, we conclude that the PRD variants c.1091C>G (p.A364G), c.1097C>G (p.P366R), c.1103_1114dup 
(p.E369_T372dup) and c.1111_1122dup (p.A371_P374dup), reported as monoallelic variants in patients, are 
unlikely to be the cause of disease in these patients. The c.1103_1114dup (p.E369_T372dup) and c.1111_1122dup 
(p.A371_P374dup) duplications translate to an identical product that does not result in the addition or loss of 
any proline-rich motifs (PRM), and may thus not significantly impact the repetitive unstructured PRD.
Finally, the PRD variant c.1053_1064delTGC AGA GCC ACC (p.A352_P355del) (Fig. 8) has been reported to 
cause adCORD or early-onset  RP26. The pathogenesis of this variant was investigated in transgenic mouse models 
in which the wild-type or the c.1053_1064delTGC AGA GCC ACC (p.A352_P355del) human AIPL1 transgene 
under the control of the mouse cone/rod Crx promoter was expressed in an Aipl1 null  background52. In single 
transgenic mice, the mutant transgene led to a CORD phenotype, predominantly leading to a slow and progres-
sive cone degeneration with near complete loss of cones at P125, and early photopic defects preceding cone 
loss. Progressive rod photoreceptor degeneration was considerably delayed compared to cone degeneration and 
stabilised after P90. Decreased levels of rod PDE6α, rod PDE6β, PDE6γ and cone PDE6α’ were observed in these 
animals at P16 before the onset of cone and rod degeneration. In double transgenic mice, the p.A352_P355del 
was shown to have a dominant negative effect on wild-type human AIPL1, but not on wild-type murine Aipl1, 
which was able to rescue the CORD phenotype, confirming that the dominant negative effect of p.A352_P355del 
is mediated through the PRD. However, this study also showed that the pathogenesis mediated by this disease-
causing variant differs in rods and cones. An ~ 40–50 fold excess of AAV-delivered wild type human AIPL1 rela-
tive to p.A352_P355del AIPL1 rescued cone-mediated photopic vision and restored the levels of cone PDE6α’. 
However, the excess levels of human AIPL1 did not restore rod-mediated scotopic vision, and while the near 
statistically relevant rescue of PDE6α and PDE6β were achieved, no rescue of PDE6γ was achieved. Thus, the 
deficit in PDE6γ occurs independently of either the presence or absence of wild-type AIPL1, pointing to a 
dominant gain-of-function in these cells. This pathogenic effect might be mediated via as of yet unidentified 
photoreceptor-specific interacting protein(s). Our in vitro functional assays showed that p.A352_P355del did 
not lead to a significant defect in either HSP90 interaction or cGMP modulation. However, our assay entails 
the heterologous reconstitution of rod PDE6α, PDE6β and PDE6γ in the absence of photoreceptor-specific pro-
teins, and we conclude that while our assay is useful for the functional validation of loss-of-function mutations, 
it is not suitable for the validation of dominant disease involving a gain-of-function mechanism. To date, the 
c.1053_1064delTGC AGA GCC ACC (p.A352_P355del) variant is the only AIPL1 sequence variant associated 
with a dominantly inherited phenotype. The other PRD variants investigated in this study are all associated 
with autosomal recessive loss-of-function disease, and we conclude from our assays that these variants are not 
disease-associated.
In summary, we confirm the disease-causing status of sequence variants in the FKBP-like and TPR domains of 
AIPL1, as well as within the linker between these domains, and confirm that p.Q298H is a rare benign variant. We 
also show that certain variants (p.G122R) may behave as rare hypomorphic alleles, thus improving the prospects 
of timely therapeutic intervention for these patients. Finally, we show that the PRD of AIPL1 is dispensable for 
both HSP90 interaction and PDE6 activity, and that variants in this domain do not lead to deficits in the modula-
tion of cGMP levels. We confirm that the PRD variants investigated do not cause disease, with the exception of 
p.A352_P355del associated with adCORD, which causes pathogenesis via alternative PRD-mediated dominant 
negative and gain-of-function mechanisms mediated by this domain.
Materials and methods
AIPL1 sequence variations, nomenclature and in silico analysis. In this study, we investigated 21 
molecularly confirmed homozygous, compound heterozygous or heterozygous AIPL1 variations (missense, 
nonsense, insertions, duplications or deletions) in new and previously reported cases of patients with retinal 
degeneration. The AIPL1 coding sequence is numbered according to the Ensembl Transcript ENST00000381129 
(RefSeq NM_014336, NP_055151) where the cDNA uses + 1 as the ATG translation initiation codon, with the 
initiation codon designated as codon 1. Nomenclature of AIPL1 sequence variations followed HGVS (Human 
Genome Variation Society, in the public domain https ://varno men.hgvs.org) standards. AIPL1 variations were 
investigated using two in silico software prediction programmes: SIFT (Sorting Intolerant From Tolerant; in the 
public domain, https ://sift.jcvi.org) and PolyPhen-2 (Polymorphism Phenotyping v2; in the public domain, https 
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://genet ics.bwh.harva rd.edu/pph/index .html). Phyre2 was used to build a working model of the AIPL1  protein53 
and the model was visualised with the PyMol (Schrödinger Inc, USA).
DNA manipulation and plasmids. General DNA methods were performed using standard techniques. 
For cloning and amplification of plasmid DNA, the Escherichia coli strain DH5α (fhuA2 Δ(argF-lacZ)U169 phoA 
glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17) from New England Biolabs (NEB) was used. 
Expression of myc-tagged AIPL1 was carried out using pCMV-Tag3C-AIPL1  plasmid54. AIPL1 mutagenesis 
was undertaken by PCR site-directed mutagenesis (SDM) using the Q5 Site-Directed Mutagenesis Kit (NEB). 
Primers were designed using NEBaseChanger software (in the public domain, https ://nebas echan ger.neb.com), 
and SDM PCRs were conducted according to suggested conditions. AIPL1 sequences were checked by Sanger 
sequencing (Source Bioscience). To express rod PDE6 subunits in cells, pcDNA3.1AXpress-PDE6α, pCMV-HA-
PDE6β and pCMV-Myc-PDE6γ were  used5.
Cell culture and transfection. Dulbecco’s modified Eagle’s medium DMEM (Invitrogen) with 10% heat 
inactivated fetal bovine serum (FBS), 100 units/ml of penicillin and 100 µg/ml of streptomycin was used to 
culture Chinese Hamster Ovary (CHO) and HEK293T (human embryonic kidney) cells with an atmosphere of 
6%  CO2 at 37 °C. For immunofluorescence, cells were seeded into eight-well chamber slides (3.5 × 104 cells per 
well). In order to obtain protein extracts, cells were seeded into six-well plates (5 × 105 cells per well). Plasmids 
were transfected using TransIT-LT1 transfection reagent according to the manufacturer’s instructions (Mirus).
Immunocytochemistry. 24 h after transfection, CHO cells were washed twice with phosphate buffered 
saline (PBS), then fixed with 4% paraformaldehyde for 10  min and permeabilized in 0.5% triton X-100 for 
another 10 min. Blocking was performed using 3% BSA, 10% goat serum in PBS for 1 h at room temperature. A 
1h incubation with primary antibody mouse monoclonal anti-myc (1:1000) (clone 9E10, Sigma) was followed 
by 3 washes with PBS and a 1h incubation with secondary donkey anti-mouse Alexa 488 antibody (1:600) (Ther-
moFisher Scientific). After 3 washes with PBS, cells were incubated with DAPI (2 mg/ml) for 5 min, mounted in 
fluorescent mounting medium (Dako) and visualized with a Zeiss LSM710 laser scanning confocal microscope. 
The images were exported from LSM Browser and processed using ImageJ and Adobe Photoshop.
Cells extracts and immunoblotting. Transfected cells were washed in cold PBS and lysed on ice in RIPA 
buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) 
with 2% protease inhibitor cocktail (Sigma). Cells were scraped, sonicated and centrifuged at 13,000 rpm for 
30 min at 4 °C. The supernatant was collected and determination of the protein concentration was carried out 
using the BCA assay (ThermoScientific). Protein extracts were resolved by denaturing SDS-PAGE and trans-
ferred onto nitrocellulose membranes. Mouse monoclonal anti-myc (1:1000) (clone 9E10, Sigma) and rabbit 
polyclonal antisera anti-AIPL1 (1:1000) (Ab-hAIPL1)1 antibodies ware used to immunodetect AIPL1 protein 
variants. GAPDH inmunodetection using mouse monoclonal anti-GAPDH (1:30,000) (Sigma) served as a 
loading control. Goat anti-mouse (1:30,000) and anti-rabbit (1:30,000) secondary antibodies conjugated with 
horseradish peroxidase were from Pierce Biotechnology. Chemiluminescent detection was performed using the 
Luminata Crescendo (Millipore) reagent. Western blot densitometry was carried out using ImageJ.
HSP90 ELISA binding assay. Assays were performed as described in Sacristan-Reviriego et al.5. Briefly, 
purified HSP90α or HSP90β (80 nM) were incubated in Immulon 4HBX 96-well plates (Fisher Scientific) for 
at least 1 h at 4 °C. 96-well plates were blocked using 1% blocking reagent (Sigma) in the same buffer (100 mM 
 NaHCO3 pH 8.5) for 1 h and then washed 3 times with chilled TBST (50 mM Tris HCl pH 7.5, 150 mM NaCl, 
0.075% Tween-20) to remove excess protein. Cell lysates from transfected cells with wild type (w/t) AIPL1 or 
AIPL1 variants were prepared as described above and added to the wells in lysis buffer (20 mM Tris HCl pH 
7.5, 100 mM NaCl, 5 mM  MgCl2, 0.075% Tween-20) containing 2% protease inhibitor cocktail. After a 1 h incu-
bation at 4 °C, wells were washed 5 times with chilled lysis buffer. Incubation with mouse anti-myc antibody 
(1:1000) for 1 h was followed by 5 washes and another 1 h incubation with anti-mouse HRP conjugated antibody 
(1:10,000). After 5 final washes, the plate was incubated with substrate 3,3′,5,5′-tetramethylbenzidine (TMB) 
(Sigma) for colorimetric detection at 30 °C for 30 min. The reaction was stopped using 0.5 M  H2SO4 and the 
absorbance measured at 450 nm. For comparison of the AIPL1 variants to w/t AIPL1, the absorbance measured 
at 450 nm was normalised to the expression level in cell lysates detected by SDS-PAGE and western blotting.
PDE6 activity assay. Determination of intracellular cGMP concentration from acetylated samples was 
carried out using the Cyclic GMP ELISA Kit (Cayman Chemical) as described in Sacristan-Reviriego et al.5. In 
brief, cells were lysed in 0.1 M H Cl at room temperature and the supernatant was obtained after centrifugation 
at 3000 rpm for 10 min. The assays were done in triplicate and repeated at least three times.
Statistical analysis. Statistical analyses to determine p values for intergroup comparisons were conducted 
using the unpaired Student t-test. p > 0.01 was considered not significant (NS).
Ethics. All procedures were adherent to the tenets of the Declaration of Helsinki and carried out with 
approved protocols of Moorfields Eye Hospital and the Montpellier University Hospital. All procedures were 
approved by Moorfields Eye Hospital Ethics Committee and the Ministry of Public Health under the authoriza-
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tion number 11018S, and were performed with written informed consent from patients or legal guardians in the 
case of children.
Data availability
Data produced and analysed in this study are available from the corresponding author on request.
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